We have located links that may give you full text access.
Journal Article
Review
Efficacy and Safety of Citalopram for the Treatment of Poststroke Depression: A Meta-Analysis.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association 2018 September 8
OBJECTIVE: To objectively evaluate the efficacy and safety of citalopram versus other antidepressant drugs in poststroke depression (PSD) treatment.
METHODS: We searched randomized controlled trials (RCTs) that compared citalopram with other Selective serotonin reuptake inhibitors (SSRIs) and Serotonin norepinephrine reuptake inhibitor (SNRIs) on PSD treatment. The methodological quality of RCTs was assessed according to the Cochrane risk of bias tool. Meta-analysis was conducted using RevMan 5.3 software with standard mean difference (SMD) or Relative risk (RR) and their 95% confidence interval (CI).
RESULTS: A total of 20 studies involving 1485 patients were included .The RR of efficacy index compared to other SSRIs was 1.04 [95% CI: .98-1.09, P = .17], and to SNRIs was 1.01 [95% CI: .93-1.09, P = .83]. The RR of cure index compared to other SSRIs was .99 [95% CI: .82-1.19, P = .88], and to SNRIs was .95 [95% CI: .71-1.27, P = .74]. Significant decreases on Hamilton Depression Scale scores were observed in favor of citalopram when compared to other SSRIs after 4-, 6-week treatment [SMD = -.44, 95% CI: -.85 to -.03, P = .03; SMD = -.50, 95% CI: -.98 to -.02, P = .04], and no significant difference was found with SNRIs in any week [P > .05]. The rate of adverse effects also showed no significant difference between citalopram and other antidepressants [P > .05].
CONCLUSIONS: This meta-analysis indicates that the efficacy of citalopram is similar to that of other SSRIs and SNRIs, but citalopram takes action faster than other SSRIs. The adverse effects of citalopram have no significant difference compared to other antidepressants and those adverse effects are less and mild.
METHODS: We searched randomized controlled trials (RCTs) that compared citalopram with other Selective serotonin reuptake inhibitors (SSRIs) and Serotonin norepinephrine reuptake inhibitor (SNRIs) on PSD treatment. The methodological quality of RCTs was assessed according to the Cochrane risk of bias tool. Meta-analysis was conducted using RevMan 5.3 software with standard mean difference (SMD) or Relative risk (RR) and their 95% confidence interval (CI).
RESULTS: A total of 20 studies involving 1485 patients were included .The RR of efficacy index compared to other SSRIs was 1.04 [95% CI: .98-1.09, P = .17], and to SNRIs was 1.01 [95% CI: .93-1.09, P = .83]. The RR of cure index compared to other SSRIs was .99 [95% CI: .82-1.19, P = .88], and to SNRIs was .95 [95% CI: .71-1.27, P = .74]. Significant decreases on Hamilton Depression Scale scores were observed in favor of citalopram when compared to other SSRIs after 4-, 6-week treatment [SMD = -.44, 95% CI: -.85 to -.03, P = .03; SMD = -.50, 95% CI: -.98 to -.02, P = .04], and no significant difference was found with SNRIs in any week [P > .05]. The rate of adverse effects also showed no significant difference between citalopram and other antidepressants [P > .05].
CONCLUSIONS: This meta-analysis indicates that the efficacy of citalopram is similar to that of other SSRIs and SNRIs, but citalopram takes action faster than other SSRIs. The adverse effects of citalopram have no significant difference compared to other antidepressants and those adverse effects are less and mild.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app